ArticleClinical chemistry2019
ProBNP That Is Not Glycosylated at Threonine 71 Is Decreased with Obesity in Patients with Heart Failure.
Article in Clinical chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 40 citations in OpenAlex.
- Obesity and Serial NT-proBNP Levels in Guided Medical Therapy for Heart Failure With Reduced Ejection Fraction: Insights From the GUIDE-IT Trial.Journal of the American Heart Association · 2021Trial
- Obesity in Cardiorenal syndrome: Management Opportunities and Challenges.Current hypertension reports · 2025Review
- Lower NT-proBNP plasma concentrations in Pacific peoples with heart failure.ESC heart failure · 2025Article
- Development of an SI-traceable N-terminal pro-B-type natriuretic peptide certified reference material using structure-based impurity-corrected isotope dilution mass spectrometry approaches.Analytical and bioanalytical chemistry · 2024Article
- Body Composition Measures and N-terminal pro-B-type Natriuretic Peptide (NT-pro-BNP) in US Adults.Clinical chemistry · 2023Article
- A State of Natriuretic Peptide Deficiency.Endocrine reviews · 2023Article
- The Predictive Value of A, B, and C-Type Natriuretic Peptides in People at Risk of Heart Disease: Protocol for a Longitudinal Observational Study.JMIR research protocols · 2023Article
- Clinical effect of obesity on N-terminal pro-B-type natriuretic peptide cut-off concentrations for the diagnosis of acute heart failure.European journal of heart failure · 2022Article
- Biochemistry of the Endocrine Heart.Biology · 2022Review
- Review
- NT-proBNP/BNP ratio for prognostication in European Caucasian patients enrolled in a heart failure prevention programme.ESC heart failure · 2021Article
- The relationship between body mass index and N-terminal pro-B-type natriuretic peptide in community-acquired pneumonia.European journal of clinical nutrition · 2021Observational
- Cardiac natriuretic peptides.Nature reviews. Cardiology · 2020Review
- ProBNP processing is decreased by obesity in patients with heart failure.Annals of translational medicine · 2020Article
- Reference glycan structure libraries of primary human cardiomyocytes and pluripotent stem cell-derived cardiomyocytes reveal cell-type and culture stage-specific glycan phenotypes.Journal of molecular and cellular cardiology · 2020Article
- Heart Failure and Body Habitus: What Would Be the Confounding Factors of Outcome Prediction in Obese Patients with Heart Failure?International journal of heart failure · 2020Article
- Glycosylation of natriuretic peptides in obese heart failure: mechanistic insights.Annals of translational medicine · 2019Article
- Does impaired processing of pro-B-type (or brain) natriuretic peptide cause decreased plasma BNP levels in obese heart failure patients?Annals of translational medicine · 2019Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHeart failure (HF) is a leading cause of morbidity and mortality worldwide. Plasma concentrations of B-type natriuretic peptide (BNP) or its amino terminal congener (NT-proBNP) are used for HF diagnosis and risk stratification. Because BNP concentrations are inexplicably lowered in obese patients, we investigated the relationship between proBNP glycosylation, plasma NT-proBNP, and body mass index (BMI) in HF patients.
methodsThree assays were developed to distinguish between total proBNP (glycosylated plus nonglycosylated proBNP), proBNP not glycosylated at threonine 71 (NG-T71), and proBNP not glycosylated in the central region (NG-C). Intraassay and interassay CVs were <15%; limits of detection were <21 ng/L; and samples diluted in parallel.
resultApplying these assays and an NT-proBNP assay to plasma samples from 106 healthy volunteers and 238 HF patients determined that concentrations [median (interquartile range)] of proBNP, NG-T71, and NT-proBNP were greater in HF patients compared with controls [300 (44-664), 114 (18-254), and 179 (880-3459) ng/L vs 36 (18-229), 36 (18-175), and 40 (17-68) ng/L, respectively; all
conclusionsIncreased BMI is associated with decreased concentrations of proBNP not glycosylated at T71. Decreased proBNP substrate amenable to processing could partially explain the lower NT-proBNP and BNP concentrations observed in obese individuals, including those presenting with HF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.